NCT02268929 (PDM-ProValueGP) is a NA clinical trial of Accu-Chek Smart Pix Software in Diabetes Mellitus, Type 2, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT02268929?

NCT02268929 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT02268929?

Interventions in NCT02268929: Accu-Chek Smart Pix Software, Accu-Chek Smart Pix readout Device.

What condition does NCT02268929 study?

NCT02268929 studies Diabetes Mellitus, Type 2.

Is NCT02268929 still recruiting?

NCT02268929 is currently completed. Last updated 24 November 2017.

Last reviewed 2017-11-24 · How we verify

NCT02268929: PDM-ProValueGP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

Completed NA Last updated 24 November 2017

What this trial tests

NA trial testing Accu-Chek Smart Pix Software in Diabetes Mellitus, Type 2 in 414 participants. Completed in 9 February 2017.

Timeline

14 October 2014

Primary endpoint
11 January 2017

9 February 2017

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	414
Start date	14 October 2014
Primary completion	11 January 2017
Estimated completion	9 February 2017
Sites	50 locations across Germany

Drugs / interventions tested

Accu-Chek Smart Pix Software
Accu-Chek Smart Pix readout Device

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a German, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated PDM care by measuring HbA1c levels in patients with Type 2 Diabetes. Patients will be randomized into two groups to use Accu-Chek Smartpix software and Accu-Chek Smartpix device.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Benefit of Digital Tools Used for Integrated Personalized Diabetes Management: Results From the PDM-ProValue Study Program.
Heinemann L, Schramm W, Koenig H, Moritz A, et al · · 2020 · cited 12× · PMID 31378074 · DOI 10.1177/1932296819867686

Verify or expand the search:

Other trials of Accu-Chek Smart Pix Software

Trials testing the same drug.

NCT02156349 — A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patien · NA · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02268929 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 24 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02268929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing